US FDA Requests Ranitidine Removal But Also Encourages Research For Stable Formulations
Executive Summary
FDA requests immediate removal of ranitidine OTC and Rx drugs after third-party testing finds contaminant NDMA increases during storage, especially at higher temperatures. CDER Director Janet Woodcock asks firms to reformulate products to be stable as the ingredient remains approved.
You may also be interested in...
Perrigo's Recall Flushes Ranitidine OTC Private Label And Store Brand Products From US Market
Also added to FDA recalls database are multiple variations of GSK's Advil line found not to include required safety warning information; a California contract manufacturer's 12 protein products due to an unapproved herbicide; and cosmetics firm Tween Brands' third recall in nine months due to an unapproved colorant.
EMA Advocates Suspension Of All Ranitidine Drugs In EU
Concerns over the presence of a probable human carcinogen will likely see marketing of all ranitidine-containing drugs suspended across the European Union.
Ranitidine’s US Future In Limbo As Tests Continue; ‘Glow-Boosting’ Mask Also Among Recent Recalls
Zantac marketer Sanofi says it’s unclear whether the product eventually will relaunch. In other recent consumer health and beauty recalls in US, a vitamin C-containing face mask is recalled following a “spike in complaints” about skin irritation and the insides of tubes of sodium chloride ophthalmic ointments made for Walgreens and CVS were found with materials used to make the containers.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: